Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof

Patent No. EP3401335 (titled "Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof") was filed by Genentech on Jan 28, 2009. The application was issued on Jun 30, 2021.

Patent Summary

A composition for treating HER2 positive cancers that contains a main species HER2 antibody that binds to domain II of HER2 and acidic variants of that antibody. The main species antibody is the predominant antibody in the composition. The acidic variants can have modifications like deamidation, disulfide reduction, or glycosylation changes. The main species antibody and variants all bind to HER2 and have similar pharmacokinetics.

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_COA_0000914/2025Nov 27, 2025Organon, Organon HeistAppeal
UPC_COA_0000913/2025Nov 27, 2025Organon, Organon HeistAppeal
UPC_CFI_408/2025May 6, 2025F Hoffmann LA Roche, GenentechGeneric
UPC_CFI_407/2025May 6, 2025F Hoffmann LA Roche, GenentechGeneric

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3401335

GENENTECH
Application Number
EP18157419A
Filing Date
Jan 28, 2009
Status
Granted And Under Opposition
May 28, 2021
Publication Date
Jun 30, 2021